Bausch Health has acquired the rights to commercialize Glenmark’s Ryaltris olopatadine / mometasone furoate nasal spray in Canada, Glenmark has announced. According to Glenmark, which is responsible for regulatory approval under the agreement with Bausch, Health Canada is currently reviewing the company’s marketing application for Ryaltris for the treatment of seasonal allergic rhinitis.
Hikma Pharmaceuticals acquired US rights Ryaltris in February 2020, and Menarini aquired European rights to Ryaltris in December 2020. The FDA issued a complete response letter to Glenmark’s NDA for Ryaltris in June 2019; the company says that the NDA is currently under review.
Glenmark Pharmaceuticals President & Business Head, North America, Sanjeev Krishan commented, “We are pleased to partner with Bausch Health Canada, and recognize their strong foothold in the prescription and OTC market in Canada. This agreement will help us reach a larger patient population and extend the multiple benefits of Ryaltris to a significant market. Glenmark continues to build a strong portfolio in respiratory medicine, and Ryaltris marks our first true global brand launch till date.”
Bausch Health, Canada President Richard Lajoie said, “We are pleased to add Ryaltris to our allergy product portfolio and eager to make it available to Canadian patients suffering from allergies.”
Read the Glenmark Pharmaceuticals press release.
